- Home
- CHRS vs AOUT Comparison
CHRS vs AOUT Comparison
Compare CHRS & AOUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- AOUT
- Stock Information
- Founded
- CHRS 2010
- AOUT 2020
- Country
- CHRS United States
- AOUT United States
- Employees
- CHRS N/A
- AOUT N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- AOUT Ordnance And Accessories
- Sector
- CHRS Health Care
- AOUT Industrials
- Exchange
- CHRS Nasdaq
- AOUT Nasdaq
- Market Cap
- CHRS 191.3M
- AOUT 195.7M
- IPO Year
- CHRS 2014
- AOUT N/A
- Fundamental
- Price
- CHRS $1.24
- AOUT $16.74
- Analyst Decision
- CHRS Strong Buy
- AOUT Strong Buy
- Analyst Count
- CHRS 4
- AOUT 2
- Target Price
- CHRS $5.38
- AOUT $12.50
- AVG Volume (30 Days)
- CHRS 2.0M
- AOUT 76.7K
- Earning Date
- CHRS 03-12-2025
- AOUT 03-06-2025
- Dividend Yield
- CHRS N/A
- AOUT N/A
- EPS Growth
- CHRS N/A
- AOUT N/A
- EPS
- CHRS N/A
- AOUT N/A
- Revenue
- CHRS $304,340,000.00
- AOUT $201,598,000.00
- Revenue This Year
- CHRS $2.47
- AOUT $5.63
- Revenue Next Year
- CHRS N/A
- AOUT $6.85
- P/E Ratio
- CHRS N/A
- AOUT N/A
- Revenue Growth
- CHRS 44.19
- AOUT 3.66
- 52 Week Low
- CHRS $0.66
- AOUT $7.45
- 52 Week High
- CHRS $2.87
- AOUT $17.08
- Technical
- Relative Strength Index (RSI)
- CHRS 37.51
- AOUT 67.29
- Support Level
- CHRS $1.38
- AOUT $14.68
- Resistance Level
- CHRS $1.45
- AOUT $17.08
- Average True Range (ATR)
- CHRS 0.13
- AOUT 0.84
- MACD
- CHRS -0.04
- AOUT -0.04
- Stochastic Oscillator
- CHRS 4.50
- AOUT 85.83
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About AOUT American Outdoor Brands Inc.
American Outdoor Brands Inc is engaged in the business of providing outdoor products and accessories for hunting, fishing, camping, shooting, and personal security and defense products. The company designs and produces products and accessories, including shooting supplies, rest, vaults, and other related accessories; premium sportsman knives and tools for fishing and hunting; land management tools for hunting preparedness; harvesting products for post-hunt or post-fishing activities; electro-optical devices, including hunting optics, firearm aiming devices, flashlights, and laser grips; reloading, gunsmithing, and firearm cleaning supplies; and survival, camping, and emergency preparedness products.